Cingulate (CING) 10-K 10 Mar 23 2022 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 03, 2023	Jun. 30, 2022
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-40874
Entity Registrant Name	Cingulate Inc.
Entity Central Index Key	0001862150
Entity Tax Identification Number	86-3825535
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1901 W. 47th Place
Entity Address, City or Town	Kansas City
Entity Address, State or Province	KS
Entity Address, Postal Zip Code	66205
City Area Code	(913)
Local Phone Number	942-2300
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 11.5
Entity Common Stock, Shares Outstanding		11,309,412
Documents Incorporated by Reference [Text Block]	None.
ICFR Auditor Attestation Flag	false
Auditor Name	KPMG LLP
Auditor Firm ID	185
Auditor Location	Kansas City, Missouri
Common Stock, Par Value $0.0001 Per Share [Member]
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	CING
Security Exchange Name	NASDAQ
Warrants Exercisable For One Share of Common Stock [Member]
Title of 12(b) Security	Warrants, exercisable for one share of common stock
Trading Symbol	CINGW
Security Exchange Name	NASDAQ

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 5,356,276	$ 16,492,745
Short-term investments		933
Miscellaneous receivables	234,432	690,248
Prepaid expenses and other current assets	2,278,944	1,698,353
Total current assets	7,869,652	18,882,279
Property and equipment, net	2,904,787	3,145,378
Operating lease right-of-use assets	630,618	858,600
Total assets	11,405,057	22,886,257
Current liabilities:
Accounts payable	762,357	264,687
Accrued expenses	894,635	601,300
Note payable	5,000,000
Finance lease liability, current	16,053	15,096
Operating lease liability, current	339,755	295,595
Total current liabilities	7,012,800	1,176,678
Long-term liabilities:
Finance lease liability, net of current	21,487	37,534
Operating lease liability, net of current	488,748	828,503
Total long-term liabilities	510,235	866,037
Total liabilities	7,523,035	2,042,715
Stockholders’ Equity
Common Stock, $0.0001 par value; 240,000,000 shares authorized and 11,309,412 shares issued and outstanding as of December 31, 2022 and 2021	1,131	1,131
Preferred Stock, $0.0001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding as of December 31, 2022 and 2021
Additional Paid-in-Capital	73,289,387	72,574,510
Accumulated other comprehensive income		165
Accumulated deficit	(69,408,496)	(51,732,264)
Total stockholders’ equity	3,882,022	20,843,542
Total liabilities and stockholders’ equity	$ 11,405,057	$ 22,886,257

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	240,000,000	240,000,000
Common stock, shares issued	11,309,412	11,309,412
Common stock, shares outstanding	11,309,412	11,309,412
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 8,995,280	$ 8,410,489
General and administrative	8,506,438	12,268,909
Operating loss	(17,501,718)	(20,679,398)
Interest and other expense, net	(174,514)	(30,593)
Loss before income taxes	(17,676,232)	(20,709,991)
Income tax benefit (expense)
Net loss and Comprehensive loss	$ (17,676,232)	$ (20,709,991)
Net loss per share of common stock, basic and diluted	$ (1.56)	$ (2.79)
Weighted average number of shares used in computing net loss per share of common stock, basic and diluted	11,309,412	7,413,579

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Members Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2020			$ 32,314,543	$ (31,022,273)	$ 165	$ 1,292,435
Balance, shares at Dec. 31, 2020
Members’ capital contributions			7,104,957			7,104,957
Unrealized losses on short-term investments
Common stock issued in IPO, net of issuance costs of $4,627,079	$ 417	20,373,801				20,374,218
Common stock issued in IPO, net of issuance costs of $4,627,079, shares	4,166,666
Stock-based compensation expense		43,835				43,835
Conversion of LLC units to common stock in connection with Reorganization Merger	$ 714	39,418,786	(39,419,500)
Conversion of LLC units to common stock in connection with Reorganization Merger, shares	7,142,746
Modification of profits interests units in connection with Reorganization Merger		12,738,088				12,738,088
Net loss				(20,709,991)		(20,709,991)
Balance at Dec. 31, 2021	$ 1,131	72,574,510		(51,732,264)	165	20,843,542
Balance, shares at Dec. 31, 2021	11,309,412
Stock-based compensation expense		800,796				800,796
Net loss				(17,676,232)		(17,676,232)
Available for sale investments					(165)	(165)
IPO issuance costs		(85,919)				(85,919)
Balance at Dec. 31, 2022	$ 1,131	$ 73,289,387		$ (69,408,496)		$ 3,882,022
Balance, shares at Dec. 31, 2022	11,309,412

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Dec. 31, 2021 USD ($)
Statement of Stockholders' Equity [Abstract]
Stock issuance costs	$ 4,627,079

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating activities:
Net loss	$ (17,676,232)	$ (20,709,991)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	394,011	708,317
Noncash compensation expense relating to modification of profits interest units		12,738,088
Stock-based compensation	800,796	43,835
Changes in operating assets and liabilities:
Miscellaneous receivables	455,816	(538,476)
Prepaid expenses and other current assets	(580,591)	(1,258,857)
Operating lease right-of-use assets	227,982	100,124
Trade accounts payable and accrued expenses	791,005	(1,324,686)
Current portion of operating lease liability	44,160	61,427
Long-term portion of operating lease liability	(339,755)	(228,938)
Other liabilities		(23,615)
Net cash used in operating activities	(15,882,808)	(10,432,772)
Investing activities:
Purchase of property and equipment	(153,420)	(814,736)
Proceeds from sale of short-term investments	933
Other	(165)
Net cash used in investing activities	(152,652)	(814,736)
Financing Activities:
Proceeds from the issuance of common stock in initial public offering, net		20,374,218
IPO issuance costs	(85,919)
Members’ capital contributions		7,104,957
Payments on notes payable		(500,335)
Proceeds from note payable	5,000,000
Principal payments on finance lease obligations	(15,090)	(436,259)
Net cash provided by financing activities	4,898,991	26,542,581
Cash and cash equivalents:
Net decrease in cash and cash equivalents	(11,136,469)	15,295,073
Cash and cash equivalents at beginning of year	16,492,745	1,197,672
Cash and cash equivalents at end of year	5,356,276	16,492,745
Non-cash activities
Property and equipment accrued but not paid at end of year		279,730
Cash payments:
Interest paid	$ 19,000	$ 114,725

Nature of the Business and Liqu

Nature of the Business and Liquidity	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of the Business and Liquidity	(1) Nature of the Business and Liquidity Organization Cingulate Inc. is a biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. CTx-1301 and CTx-1302 utilize a flexible core tableting technology with target product profile designed to deliver a rapid onset and last the entire active day with a controlled descent of plasma drug level and have favorable tolerability. The Company has initiated Phase 3 clinical trials for CTx-1301, with first patients in the adult dose-optimization study dosed in early 2023. In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. On November 14, 2012, Cingulate Therapeutics LLC (CTx), a Delaware limited liability company, was formed. On May 10, 2021, Cingulate Inc. (Cingulate, or the Company), a Delaware corporation and wholly-owned subsidiary of CTx, was formed to serve as a holding company, in anticipation of the Company becoming publicly traded. Through a Reorganization Merger which occurred in the third quarter of 2021, Cingulate effectively acquired CTx and all outstanding units of CTx were converted into shares of Cingulate common stock. CTx remains the entity through which the Company conducts operations. CTx is the predecessor of Cingulate for financial reporting purposes. The consolidated financial statements and notes for the years ended December 31, 2022 and 2021 represent the full consolidation of Cingulate and its subsidiaries, including CTx and all references to the Company represent this full consolidation. Liquidity The Company has incurred losses and negative cash flows from operations since inception. As a pre-revenue entity, the Company is dependent on the ability to raise capital to support operations until such time as the product candidates under development are U.S Food and Drug Administration (FDA) approved, manufactured, commercially available to the marketplace and produce revenues. The IPO, which was completed in December 2021, provided the Company the ability to continue its research and development activities. In addition, the Company received proceeds of $ 5.0 2,650,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies (a) Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. (b) Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. (c) Concentration of Credit Risk The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $ 250,000 (d) Cash and Cash Equivalents Bank demand deposit accounts and short-term liquid investments with an initial maturity of three months or less are considered cash and cash equivalents. Cash and cash equivalents as of December 31, 2022 and 2021 consisted of bank deposits and short-term money market funds. Cash and cash equivalents are carried at cost which is indicative of fair value. (e) Miscellaneous Receivables Miscellaneous receivables consist of payroll tax credits generated from the Company’s 2021 and 2020 federal income tax returns, which have not yet been received, as well as employee retention tax credits for payroll costs incurred in those years. The Company analyzed IAS 20, Accounting for Government Grants and Disclosure of Government Assistance (f) Property and Equipment, net Property and equipment, net are stated at cost, less accumulated depreciation. Maintenance and repairs are charged to expense when incurred. Property and equipment are depreciated using the straight-line method over the estimated remaining useful lives or, for leasehold improvements or leased assets under a financing lease, the life of the lease if shorter. (g) Leases The Company is a lessee in two noncancellable operating leases, relating to office space at the Kansas City headquarters office and the New Jersey office and two finance leases, for certain furniture and equipment, one of which the lease term ended on December 31, 2021. The Company determines if an arrangement is or contains a lease at contract inception. The Company recognizes a ROU asset and a lease liability at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method. The Company determines the discount rate it uses to discount the unpaid lease payments to present value, which requires management judgement. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit rate was stated in the agreement for one of the Company’s leases; however, for the others, the implicit rate was not determinable as the Company did not have access to the lessor’s estimated residual value or the amount of the lessor’s deferred initial direct costs. Therefore, the Company uses its incremental borrowing rate as the discount rate for these leases. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company has not been able to borrow on a collateralized basis, it has determined a synthetic credit rating based on factors that a credit rating agency would typically analyze when establishing an entity’s credit rating. Due to the fact that the Company is a pre-revenue entity, the Company determined that its incremental borrowing rate should be based on the composite CCC and lower bond spreads at the lease measurement dates plus a risk-free rate based on specific lease maturities. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of cumulative lease incentives received. Lease expense is recognized on a straight-line basis over the lease term which includes the accretion of the lease liability and amortization of the ROU asset. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownerships of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. ROU assets for operating and finance leases are evaluated for impairment losses. Under the long-lived assets impairment guidance in ASC Subtopic 360-10, Property and Equipment-Overall Operating lease ROU assets are presented as operating lease right-of-use assets on the consolidated balance sheet. The current and long-term portions of operating lease liabilities are presented separately on the consolidated balance sheet. Finance lease ROU assets are included in property, plant, and equipment. The current and long-term portions of finance lease liabilities are presented separately on the consolidated balance sheet. (h) Impairment of Long-lived Assets The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No (i) Research and Development Research and development costs are expensed as incurred and include all direct and indirect costs associated with the development of the Company’s product candidates. These expenses include payments to third parties for research, development and manufacturing services, personnel costs and depreciation on manufacturing equipment. At the end of the reporting period, the Company compares payments made to third party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. (j) Stock-Based Compensation The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 11. (k) Paycheck Protection Program On March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act includes a provision for a Paycheck Protection Program (“PPP”) administered by the U.S. Small Business Administration (“SBA”) and further amended by the Paycheck Protection Program Flexibility Act of 2020 (“PPP Flexibility Act”), which was enacted on June 5, 2020. In April 2020, the Company received a PPP Loan of $ 312,500 236,457 In July 2021, the Company was notified that the first PPP loan was forgiven by the SBA and in October 2021, the Company was notified that the second PPP loan was forgiven by the SBA. The Company analyzed IAS 20, Accounting for Government Grants and Disclosure of Government Assistance (l) Segments Operating segments are components of a Company for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one operating business segment-drug development. (m) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. As of December 31, 2022, CTx is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items, therefore a full valuation allowance is recorded. The Company has not identified any uncertain tax positions. There have been no interest or penalties recognized in the consolidated financial statements related to uncertain tax positions. In addition, no tax positions exist for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company files income tax returns in the federal and various state jurisdictions. These federal income taxes are immaterial. The Company is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2019. (n) Common Stock Purchase Warrants The Company issued warrants in connection with its IPO in December 2021. These equity instruments were valued at fair value when they were issued. See additional information in Note 12. (o) Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration to potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive instruments outstanding during the period using the simplified method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Prepaid Expenses and Other Current Assets	(3) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following at December 31, 2022 and 2021: Schedule of Prepaid Expenses 2022 2021 Research and development $ 1,377,391 $ 643,917 Insurance 472,152 761,594 Active pharmaceutical ingredients 209,156 264,361 Deferred capital raise costs 100,339 - Professional fees 61,524 - Dues and subscriptions 37,684 - Other 20,698 28,481 Total prepaid expenses $ 2,278,944 $ 1,698,353

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	(4) Property and Equipment Property and equipment, net consists of the following at December 31, 2022 and 2021: Schedule of Property and Equipment Estimated Useful Life (in years) 2022 2021 Equipment 2 7 $ 2,565,997 $ 2,509,126 Furniture and fixtures 7 145,754 145,754 Computer equipment 5 41,898 41,898 Leasehold improvements 5 471,505 471,505 Construction-in-process- equipment - 1,739,699 1,643,150 Property and equipment, gross 4,964,853 4,811,433 Less: accumulated depreciation (2,060,066 ) (1,666,055 ) Property and equipment, net $ 2,904,787 $ 3,145,378 Depreciation expense was $ 394,011 708,317

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses	(5) Accrued Expenses Accrued expenses consisted of the following at December 31, 2022 and 2021: Schedule of Accrued Expenses 2022 2021 Interest $ 292,339 $ - Professional fees 314,446 71,570 Research and development - 250,000 CIP- Equipment - 279,730 Employee bonuses 175,625 - Other 112,225 - Total accrued expenses $ 894,635 $ 601,300

Contingencies

Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contingencies	(6) Contingencies The Company may, from time to time, be subject to legal proceedings and claims arising in the ordinary course of business and otherwise. A substantial legal liability against us could have an adverse effect on our business, financial condition and results of operations. The Company records legal costs associated with loss contingencies as incurred and establishes reserves when those matters present material loss contingencies that management determines to be both probable and reasonably estimable in accordance with ASC 450, “Contingencies.”

Related Party Notes Payable

Related Party Notes Payable	12 Months Ended
	Dec. 31, 2022
Related Party Notes Payable
Related Party Notes Payable	(7) Related Party Notes Payable On August 10, 2022, the Company received $ 5,000,000 15% Outstanding principal and all accrued and unpaid interest are due and payable on August 8, 2025, or 120 days following written demand made by WFIA during the first five business days of a calendar quarter beginning April 1, 2023. 5,000,000 During the year ended December 31, 2022, the Company recognized $ 292,339

Members_ Capital

Members’ Capital	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Members’ Capital	(8) Members’ Capital Prior to the Reorganization Merger, the Company had multiple classes of Members’ capital, comprised of Founders Units, Class B, D, E, F and G Preferred Units, and Class C Profits Interests. Class B, E, F and G Preferred Units had similar rights specifically related to cash distributions as a return of invested capital. Class D Preferred Units had all the rights of Founders and the other Classes of Preferred Units plus some additional rights noted below. All classes of Members’ capital had voting rights. The Company maintained capital accounts for each Member. 3,243,201 Class F Preferred Units The CTx Board authorized 6,984,985 11.3 rd Class G Preferred Units The CTx Board authorized 12,000,000 2,998,184 6.7 Distributions, if any, from the Company were to be made first to the holders of Class B, D, E, F and G Preferred Units, pro rata in proportion to each such Member’s unreturned capital contributions. Distributions were then to be made to all Members including Founders Units, pro rata in proportion to the number of units held by each Member, with consideration given to the applicable distribution thresholds for Class C Profits Interests at which each was issued and as disclosed in each Profits Interest Unit agreement, as further described in Note 9. Costs associated with issuance of the Units is immaterial. Pursuant to the terms of the Reorganization Merger, all Units were converted into shares of common stock of Cingulate, as further described in Note 1.

Profits Interest Plan

Profits Interest Plan	12 Months Ended
	Dec. 31, 2022
Retirement Benefits [Abstract]
Profits Interest Plan	(9) Profits Interest Plan During 2017, the CTx Board established and adopted the Cingulate Therapeutics LLC Equity Incentive Plan (the “Plan”) to provide for issuance of Class C PIU’s to employees, CTx Members, Board members and service providers of the Company, as defined in the Plan, eligible to receive PIU’s as an incentive under the Plan. PIU’s were granted at the discretion of the Board of Managers of the Company and in some cases at the discretion of the Chief Executive Officer of the Company based upon Board authorization. The PIU’s were issued at a Distribution Threshold equal to the pre-money fair market valuation of the Company at the date of issuance. The Distribution Threshold was the amount by which a cash distribution, made pro rata to all Members, if any, must have been exceeded in order for a particular PIU holder to participate in the allocated distribution beyond that threshold. Based on the terms of the award, the Distribution Threshold was treated as a performance condition for purposes of financial statement recognition. The PIU’s vesting period with respect to the service condition was defined in the PIU award agreement and ranged from 30 days to three years with an average vesting period for all PIU’s granted of 107 days. As defined in the Company’s Operating Agreement, all PIU’s issued under the Plan entitled the holder to participate pro rata in the profits, if any, of the Company over the stated Distribution Threshold, assuming a cash distribution was generally made to all Members, subject to any preference or priorities of the other classes of Units. The Class C PIU’s also held voting rights on a one-for-one basis. Immediately prior to the Reorganization Merger, the Company had granted and issued 8,500,000 , Compensation – Stock Compensation, 8.5 1,158,008 12.7 8.2 4.5 The following summarizes the activity of the Company’s Plan: Summary of Stock Option Activity Distribution Profits Interest Thresholds Units (stated in millions) Outstanding at January 1, 2021 8,142,461 $ 25 120 Issued 357,539 $ 160 Forfeited - Converted to common shares upon Reorganization Merger (8,500,000 ) Outstanding at December 31, 2021 - Prior to the Reorganization Merger, the Company had issued all units available under the Plan and all units had vested based upon the vesting period as outlined in the PIU agreement. PIUs issued and outstanding prior to the Reorganization Merger, which was also the modification date, at the various distribution thresholds were as follows: Schedule of Various Distribution Thresholds Distribution Threshold $ (in millions): Year Granted $25 $40 $75 $80 $90 $120 $160 Total 2017 4,753,000 125,200 - - - - - 4,878,200 2018 - 661,525 217,725 22,883 - - - 902,133 2019 - - - - 377,524 458,924 - 836,448 2020 - - - 1,476,126 - 49,554 - 1,525,680 2021 357,539 357,539 Total 4,753,000 786,725 217,725 1,499,009 377,524 508,478 357,539 8,500,000

Stockholders_ Equity

Stockholders’ Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Stockholders’ Equity	(10) Stockholders’ Equity The Company has authorized 240,000,000 0.0001 10,000,000 0.0001 11,309,412 7,142,746 4,166,666 6.00 20.4 The holders of common stock are entitled to one vote for each share of common stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment or provision for payment of all debts and liabilities of the Company, the holders of common stock shall be entitled to share in the remaining assets of the Company available for distribution, if any. Holders of the shares of common stock are entitled to dividends when, as and if declared by the Board of Directors. Stock Dividend On September 30, 2021, the Company effected a stock dividend of 0.029 448,045 No Reverse Stock Splits On October 12, 2021, Cingulate effected a reverse stock split of its issued and outstanding shares of common stock at a ratio of 0.699-for-1, and on November 29, 2021, Cingulate effected a second reverse stock split of its issued and outstanding shares of common stock at a ratio of 0.64259-for-1 (the “Reverse Stock Splits”). No fractional shares of common stock were issued in connection with either of the Reverse Stock Splits, and all such fractional interests were rounded down to the nearest whole number. All share data, per share data and related information for all periods presented in the accompanying consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Splits.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	(11) Stock-Based Compensation In September 2021, the Company’s board of directors and stockholders adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which provides for the grant of incentive stock options and non-qualified stock options to purchase shares of the Company’s common stock, stock appreciation rights, restricted stock units, restricted or unrestricted shares of common stock, performance shares, performance units, incentive bonus awards, other stock-based awards and other cash-based awards. No awards may be made under the 2021 Plan on or after September 24, 2031, but the 2021 Plan will continue thereafter while previously granted awards remain outstanding. The maximum number of shares of common stock available for issuance in connection with options and other awards granted under the 2021 Plan is 1,927,810 1,066,791 The number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur. The Company recorded stock-based compensation expense of $ 800,796 43,835 2,089,509 2,637,895 four years A summary of option activity under the Plan during the years ended December 31, 2022 and 2021 was as follows: Summary of Option Activity Weighted-Average Aggregate Weighted-Average Remaining Intrinsic Shares Exercise Price Contractual Term Value Outstanding at January 1, 2021 - Grants 523,285 $ 6.00 9.94 - Exercised - Forfeitures or expirations - Outstanding at December 31, 2021 523,285 Grants 417,632 $ 1.72 9.17 Exercised - Forfeitures or expirations (79,898 ) $ 3.46 Outstanding at December 31, 2022 861,019 $ 4.16 9.05 - Vested and expected to vest at December 31, 2022 861,019 Exercisable at December 31, 2022 169,027 The Company’s stock options issued qualify for equity accounting treatment under ASC 718 and are measured at fair value as of their grant date accordingly. The fair value of the options were estimated using a Black-Scholes model. The assumptions that the Company used to estimate the grant-date fair value of stock options granted to employees and directors were as follows, shown on a weighted average basis for the respective years ended: Schedule of Fair Value Assumption 2022 2021 Risk-free interest rate 1.889 % 0.012 % Expected term (in years) 5.98 6.25 Expected volatility 1.126 1.134 Expected dividend yield 0 % 0 % Risk-Free Interest Rate Expected Term: Expected Volatility Expected Dividend Yield zero The grant-date fair value of options granted during the year ended December 31, 2022 ranged from $ 0.86 1.16 5.13 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock. Because there were no stock options with exercise prices lower than the fair value of the Company’s common stock, the aggregate intrinsic value is zero as of December 31, 2022 and 2021.

Common Stock Purchase Warrants

Common Stock Purchase Warrants	12 Months Ended
	Dec. 31, 2022
Common Stock Purchase Warrants
Common Stock Purchase Warrants	(12) Common Stock Purchase Warrants For each of the 4,166,666 6.00 624,999 .001 4,791,665 6.00 warrants are exercisable from December 10, 2021 through December 10, 2026. In addition to the common stock purchase warrants noted above, the Company issued 208,333 7.50 warrants are exercisable from June 7, 2022 through December 10, 2026. The warrants were valued using a Black-Scholes model with a risk-free rate of .0082 5.0 1.24 The following table summarizes the Company’s outstanding warrants as of December 31, 2022 and 2021: Summary of Outstanding Warrants Grant Date Grant Date Number of Exercise Fair Value Fair Value Warrants Price per Warrant Total Balance- January 1, 2021 Underwritten public offering 4,791,665 $ 6.00 $ 4.77 $ 22,856,242 Issuance of underwriter warrants 208,333 $ 7.50 $ 4.64 966,665 Balance- December 31, 2021 4,999,998 $ 23,822,907 There were no warrants issued or exercised in 2022. The Company has accounted for these warrants as equity-classified instruments under ASC Subtopic 815-40, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, Schedule of Fair Value of Warrants to Additional Paid in Capital Percent Fair of Total Amount Value Fair Value Allocated Common Stock $ 25,000,000 51.2 % $ 12,800,000 Common Stock Purchase Warrants 23,822,907 48.8 % 12,200,000 Total $ 48,822,907 100 % $ 25,000,000

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	(13) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. CTx is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. No Income tax expense differed from the expected expense computed by applying U.S. Federal income tax rate for the respective years ended as follows: Schedule of Effective Income Tax Rate Reconciliation December 31, 2022 December 31, 2021 Federal income tax benefit at statutory rate $ (3,712,008 ) $ (563,519 ) State income tax benefit (977,496 ) (148,393 ) Permanent differences 11,935 44,804 Change in valuation allowance 4,733,324 713,701 Other (55,755 ) (46,593 ) Total income tax expense $ - $ - Evaluating the need for, and amount of, a valuation allowance for deferred tax assets often requires significant judgment and extensive analysis of all available evidence on a jurisdiction-by-jurisdiction basis. Such judgments require the Company to interpret existing tax law and other published guidance as applied to its circumstances. As part of this assessment, the Company considers both positive and negative evidence about its profitability and tax situation. A valuation allowance is provided if, based on available evidence, it is more likely than not that all or some portion of a deferred tax asset will not be realized. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items. The Company recorded a valuation allowance of its net deferred tax assets totaling $ 5,580,595 and $ 847,269 , respectively, at December 31, 2022 and 2021, which was recorded as a component of income tax expense on the accompanying consolidated statements of operations and other comprehensive loss. The Company files income tax returns in the U.S. federal and various state jurisdictions. The Companies are not subject to U.S. federal and state income tax examinations by tax authorities for years before 2018. The Company follows the provisions of FASB ASC 740, Income Taxes Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 31, 2021 Deferred income tax assets: Current: Research and development costs $ 343,087 $ - Other 59,018 4,050 Non-current: Net operating losses 3,381,215 1,201,974 Research and development costs 1,762,716 - Unvested stock options 204,380 11,835 Patents 92,417 90,480 Right-of-use assets 63,563 49,606 Gross deferred income tax assets 5,906,396 1,357,945 Less: valuation allowance (5,580,595 ) (847,269 ) Net deferred income tax asset 325,801 510,676 Deferred income tax liabilities: Current: Accrual to cash (11,228 ) (105,075 ) Non-current Property and equipment (314,573 ) (405,601 ) Gross deferred income tax liabilities (325,801 ) (510,676 ) Net deferred tax asset (liability) $ - $ -

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases
Leases	(14) Leases In June, 2019, the Company executed a lease, which included expansion and renovation of previously leased space for the Kansas City office. The term of the lease is for a period of five years 30,453 33,145 201,600 The Company leases office space for its New Jersey based employees from a related party, as further described in Note 17. The base rent for this lease was $ 3,000 three In 2018, the Company entered into an 18-month operating lease for manufacturing equipment. Interim rent was incurred during installation of the equipment with the lease commencing in June 2018. Monthly lease payments for this leased equipment were $ 61,786 this lease was extended for a period of twenty-four months with a monthly lease payment of $ 37,072 In April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $ 1,491 6.12 The components of lease cost for the years ended December 31, 2022 and 2021 were as follows: Summary of Components of Lease Cost 2022 2021 Operating lease cost $ 338,787 $ 338,787 Finance lease cost: Amortization of right-of-use assets 10,990 409,927 Interest on lease liabilities 2,804 26,504 Total finance lease cost 13,794 436,431 Total lease cost $ 352,581 $ 775,218 Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 were as follows: Summary of Lease Reported in Consolidated Balance Sheets 2022 2021 Operating Leases: Operating lease right-of-use assets $ 630,618 $ 858,600 Other current liabilities 339,755 295,595 Operating lease liabilities 488,748 828,503 Total operating lease liabilities 828,503 1,124,098 Finance leases: Property and equipment 76,928 76,928 Accumulated amortization (44,988 ) (29,602 ) Property and equipment, net 31,940 47,326 Current installments of obligations under finance leases 16,053 15,096 Long-term portion of obligations under finance leases 21,487 37,534 Long-term portion of obligations under finance leases 21,487 37,534 Total finance lease liabilities $ 37,540 $ 52,630 Other information relating to leases as of December 31, 2022 and 2021 was as follows: Summary of Other Information Relating to Leases 2022 2021 Supplemental cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 36,000 $ 433,172 Operating cash flow from finance leases 3,698 26,504 Financing cash flow from finance leases 15,090 436,259 Reductions to ROU assets resulting from reductions to lease obligations: Operating leases 227,981 196,245 Finance leases 10,990 409,927 Weighted average remaining lease term: Operating leases 25 39 Finance leases 27 39 Weighted average discount rate: Operating leases 11.62 % 11.57 % Finance leases 6.12 % 6.12 % Maturities of lease liabilities under noncancellable leases as of December 31, 2022 are as follows: Summary of Maturity of Lease Liabilities Operating Finance leases leases 2023 414,800 17,900 2024 393,005 17,900 2025 132,580 4,475 Thereafter - - Total undiscounted lease payments 940,385 40,275 Less imputed interest (111,882 ) (2,742 ) Total lease liabilities $ 828,503 $ 37,533

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	(15) Net Loss Per Share The following table sets forth the computation of the basic and diluted net loss per share for the year ended December 31, 2022 and 2021: Schedule of Net Loss Per Share Basic And Diluted 2022 2021 Numerator: Net loss $ (17,676,232 ) $ (20,709,991 ) Denominator: Weighted average common shares outstanding 11,309,412 7,413,579 Net loss per share, basic and diluted $ (1.56 ) $ (2.79 ) Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: Schedule of Potentially Dilutive Securities 2022 2021 Stock options issued under the 2021 Equity Incentive Plan 861,019 523,285 Common stock purchase warrants outstanding 4,999,998 4,999,998 Total 5,861,017 5,523,283

License Agreement

License Agreement	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreement	(16) License Agreement CTx has a licensing agreement with a company related to the patents and licensed know-how for use in the development of CTx-1301, CTx-1302, and CTx-2103. CTx will pay the following upon the occurrence of the following milestone events: ● $ 250,000 ● $ 250,000 ● $ 250,000 500,000 ● $ 250,000 The Company accrued the $ 250,000

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	(17) Related Party Transactions A member of the Company’s Board of Directors, is a Senior Managing Director at Laidlaw & Company (UK) Ltd. Laidlaw & Company (UK) Ltd. acted as co-lead book-running underwriter for the Company’s IPO. The discounts and commissions paid to Laidlaw & Company (UK) Ltd. in connection with the IPO were approximately $ 500,000 The general counsel of the Company is a partner with a law firm providing office facilities space that is leased by the Company. Rental expense incurred by the Company to the law firm was $ 36,000 0 A member of the Company’s Board of Directors, Peter Werth, is the manager of WFIA, the entity which provided $ 5.0 292,339 5.0 292,339

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	(18) Subsequent Events Management evaluated events that occurred subsequent to December 31, 2022 through March 10, 2023, which is the date the financial statements were issued. In January 2023, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of its common stock for aggregate proceeds of up to $ 2,650,000 3 On , the Company entered into a Joint Commercialization Agreement with Indegene, Inc., pursuant to which

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	(a) Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of Cingulate and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	(b) Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during a reporting period. Actual results could differ from estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
Concentration of Credit Risk	(c) Concentration of Credit Risk The Company maintains cash equivalent deposits, which at various times throughout the fiscal year exceeded the amounts insured by the Federal Deposit Insurance Corporation limit of $ 250,000
Cash and Cash Equivalents	(d) Cash and Cash Equivalents Bank demand deposit accounts and short-term liquid investments with an initial maturity of three months or less are considered cash and cash equivalents. Cash and cash equivalents as of December 31, 2022 and 2021 consisted of bank deposits and short-term money market funds. Cash and cash equivalents are carried at cost which is indicative of fair value.
Miscellaneous Receivables	(e) Miscellaneous Receivables Miscellaneous receivables consist of payroll tax credits generated from the Company’s 2021 and 2020 federal income tax returns, which have not yet been received, as well as employee retention tax credits for payroll costs incurred in those years. The Company analyzed IAS 20, Accounting for Government Grants and Disclosure of Government Assistance
Property and Equipment, net	(f) Property and Equipment, net Property and equipment, net are stated at cost, less accumulated depreciation. Maintenance and repairs are charged to expense when incurred. Property and equipment are depreciated using the straight-line method over the estimated remaining useful lives or, for leasehold improvements or leased assets under a financing lease, the life of the lease if shorter.
Leases	(g) Leases The Company is a lessee in two noncancellable operating leases, relating to office space at the Kansas City headquarters office and the New Jersey office and two finance leases, for certain furniture and equipment, one of which the lease term ended on December 31, 2021. The Company determines if an arrangement is or contains a lease at contract inception. The Company recognizes a ROU asset and a lease liability at the lease commencement date. For operating leases, the lease liability is initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. For finance leases, the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective-interest method. The Company determines the discount rate it uses to discount the unpaid lease payments to present value, which requires management judgement. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. The implicit rate was stated in the agreement for one of the Company’s leases; however, for the others, the implicit rate was not determinable as the Company did not have access to the lessor’s estimated residual value or the amount of the lessor’s deferred initial direct costs. Therefore, the Company uses its incremental borrowing rate as the discount rate for these leases. The Company’s incremental borrowing rate for a lease is the rate of interest it would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. Because the Company has not been able to borrow on a collateralized basis, it has determined a synthetic credit rating based on factors that a credit rating agency would typically analyze when establishing an entity’s credit rating. Due to the fact that the Company is a pre-revenue entity, the Company determined that its incremental borrowing rate should be based on the composite CCC and lower bond spreads at the lease measurement dates plus a risk-free rate based on specific lease maturities. The ROU asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of cumulative lease incentives received. Lease expense is recognized on a straight-line basis over the lease term which includes the accretion of the lease liability and amortization of the ROU asset. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownerships of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. ROU assets for operating and finance leases are evaluated for impairment losses. Under the long-lived assets impairment guidance in ASC Subtopic 360-10, Property and Equipment-Overall Operating lease ROU assets are presented as operating lease right-of-use assets on the consolidated balance sheet. The current and long-term portions of operating lease liabilities are presented separately on the consolidated balance sheet. Finance lease ROU assets are included in property, plant, and equipment. The current and long-term portions of finance lease liabilities are presented separately on the consolidated balance sheet.
Impairment of Long-lived Assets	(h) Impairment of Long-lived Assets The Company assesses the carrying value of its long-lived assets, including property and equipment, as well as lease ROU assets, when events or circumstances indicate that the carrying value of such assets may not be recoverable. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by a comparison of the carrying amount of the assets to future undiscounted cash flows expected to be generated by the assets. If the sum of the expected future cash flows is less than the carrying amount, the Company would recognize an impairment loss. An impairment loss would be measured by comparing the amount by which the carrying value exceeds the fair value of the long-lived asset groups. No
Research and Development	(i) Research and Development Research and development costs are expensed as incurred and include all direct and indirect costs associated with the development of the Company’s product candidates. These expenses include payments to third parties for research, development and manufacturing services, personnel costs and depreciation on manufacturing equipment. At the end of the reporting period, the Company compares payments made to third party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs.
Stock-Based Compensation	(j) Stock-Based Compensation The Company measures employee and director stock-based compensation expense for all stock-based awards based on their grant date fair value using the Black-Scholes option-pricing model. For stock-based awards with service conditions, stock-based compensation expense is recognized over the requisite service period using the straight-line method. Forfeitures are recognized as they occur. See additional information in Note 11.
Paycheck Protection Program	(k) Paycheck Protection Program On March 27, 2020, the U.S. federal government enacted the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act includes a provision for a Paycheck Protection Program (“PPP”) administered by the U.S. Small Business Administration (“SBA”) and further amended by the Paycheck Protection Program Flexibility Act of 2020 (“PPP Flexibility Act”), which was enacted on June 5, 2020. In April 2020, the Company received a PPP Loan of $ 312,500 236,457 In July 2021, the Company was notified that the first PPP loan was forgiven by the SBA and in October 2021, the Company was notified that the second PPP loan was forgiven by the SBA. The Company analyzed IAS 20, Accounting for Government Grants and Disclosure of Government Assistance
Segments	(l) Segments Operating segments are components of a Company for which separate financial information is available and is evaluated regularly by the Company’s chief operating decision-maker in deciding how to allocate resources and in assessing performance. The Company currently operates in one operating business segment-drug development.
Income Taxes	(m) Income Taxes Cingulate Inc. is taxed as a C corporation under the Internal Revenue Code. Cingulate Inc. records deferred income taxes to reflect the impact of temporary differences between the recorded amounts of assets and liabilities for financial reporting purposes and such amounts as measured by tax laws and regulations. As of December 31, 2022, CTx is a wholly-owned disregarded entity of Cingulate Inc., and all of the activity for CTx, along with its wholly-owned subsidiary Cingulate Works Inc., is included in the calculation of the current and deferred tax assets and liabilities for Cingulate Inc. The Company determined that it was more likely than not that it would not realize its deferred tax assets, based on historical levels of income and future forecasts of taxable income, among other items, therefore a full valuation allowance is recorded. The Company has not identified any uncertain tax positions. There have been no interest or penalties recognized in the consolidated financial statements related to uncertain tax positions. In addition, no tax positions exist for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within the next 12 months. The Company files income tax returns in the federal and various state jurisdictions. These federal income taxes are immaterial. The Company is no longer subject to U.S. federal income tax examinations by tax authorities for years before 2019.
Common Stock Purchase Warrants	(n) Common Stock Purchase Warrants The Company issued warrants in connection with its IPO in December 2021. These equity instruments were valued at fair value when they were issued. See additional information in Note 12.
Net Loss per Share	(o) Net Loss per Share Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period, without consideration to potential dilutive securities. Diluted net loss per common share is computed by dividing the net loss by the sum of the weighted average number of common shares outstanding during the period plus the number of potential dilutive instruments outstanding during the period using the simplified method. Diluted net loss per share is the same as basic net loss per share since the effect of potentially dilutive securities is anti-dilutive.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Prepaid Expenses And Other Current Assets
Schedule of Prepaid Expenses	Prepaid expenses and other current assets consisted of the following at December 31, 2022 and 2021: Schedule of Prepaid Expenses 2022 2021 Research and development $ 1,377,391 $ 643,917 Insurance 472,152 761,594 Active pharmaceutical ingredients 209,156 264,361 Deferred capital raise costs 100,339 - Professional fees 61,524 - Dues and subscriptions 37,684 - Other 20,698 28,481 Total prepaid expenses $ 2,278,944 $ 1,698,353

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consists of the following at December 31, 2022 and 2021: Schedule of Property and Equipment Estimated Useful Life (in years) 2022 2021 Equipment 2 7 $ 2,565,997 $ 2,509,126 Furniture and fixtures 7 145,754 145,754 Computer equipment 5 41,898 41,898 Leasehold improvements 5 471,505 471,505 Construction-in-process- equipment - 1,739,699 1,643,150 Property and equipment, gross 4,964,853 4,811,433 Less: accumulated depreciation (2,060,066 ) (1,666,055 ) Property and equipment, net $ 2,904,787 $ 3,145,378

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses consisted of the following at December 31, 2022 and 2021: Schedule of Accrued Expenses 2022 2021 Interest $ 292,339 $ - Professional fees 314,446 71,570 Research and development - 250,000 CIP- Equipment - 279,730 Employee bonuses 175,625 - Other 112,225 - Total accrued expenses $ 894,635 $ 601,300

Profits Interest Plan (Tables)

Profits Interest Plan (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Stock Option Activity	A summary of option activity under the Plan during the years ended December 31, 2022 and 2021 was as follows: Summary of Option Activity Weighted-Average Aggregate Weighted-Average Remaining Intrinsic Shares Exercise Price Contractual Term Value Outstanding at January 1, 2021 - Grants 523,285 $ 6.00 9.94 - Exercised - Forfeitures or expirations - Outstanding at December 31, 2021 523,285 Grants 417,632 $ 1.72 9.17 Exercised - Forfeitures or expirations (79,898 ) $ 3.46 Outstanding at December 31, 2022 861,019 $ 4.16 9.05 - Vested and expected to vest at December 31, 2022 861,019 Exercisable at December 31, 2022 169,027
Schedule of Various Distribution Thresholds	PIUs issued and outstanding prior to the Reorganization Merger, which was also the modification date, at the various distribution thresholds were as follows: Schedule of Various Distribution Thresholds Distribution Threshold $ (in millions): Year Granted $25 $40 $75 $80 $90 $120 $160 Total 2017 4,753,000 125,200 - - - - - 4,878,200 2018 - 661,525 217,725 22,883 - - - 902,133 2019 - - - - 377,524 458,924 - 836,448 2020 - - - 1,476,126 - 49,554 - 1,525,680 2021 357,539 357,539 Total 4,753,000 786,725 217,725 1,499,009 377,524 508,478 357,539 8,500,000
Equity Incentive Plan (PIU) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Stock Option Activity	The following summarizes the activity of the Company’s Plan: Summary of Stock Option Activity Distribution Profits Interest Thresholds Units (stated in millions) Outstanding at January 1, 2021 8,142,461 $ 25 120 Issued 357,539 $ 160 Forfeited - Converted to common shares upon Reorganization Merger (8,500,000 ) Outstanding at December 31, 2021 -

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Summary of Option Activity	A summary of option activity under the Plan during the years ended December 31, 2022 and 2021 was as follows: Summary of Option Activity Weighted-Average Aggregate Weighted-Average Remaining Intrinsic Shares Exercise Price Contractual Term Value Outstanding at January 1, 2021 - Grants 523,285 $ 6.00 9.94 - Exercised - Forfeitures or expirations - Outstanding at December 31, 2021 523,285 Grants 417,632 $ 1.72 9.17 Exercised - Forfeitures or expirations (79,898 ) $ 3.46 Outstanding at December 31, 2022 861,019 $ 4.16 9.05 - Vested and expected to vest at December 31, 2022 861,019 Exercisable at December 31, 2022 169,027
Schedule of Fair Value Assumption	The Company’s stock options issued qualify for equity accounting treatment under ASC 718 and are measured at fair value as of their grant date accordingly. The fair value of the options were estimated using a Black-Scholes model. The assumptions that the Company used to estimate the grant-date fair value of stock options granted to employees and directors were as follows, shown on a weighted average basis for the respective years ended: Schedule of Fair Value Assumption 2022 2021 Risk-free interest rate 1.889 % 0.012 % Expected term (in years) 5.98 6.25 Expected volatility 1.126 1.134 Expected dividend yield 0 % 0 %

Common Stock Purchase Warrants

Common Stock Purchase Warrants (Tables)	12 Months Ended
	Dec. 31, 2022
Common Stock Purchase Warrants
Summary of Outstanding Warrants	The following table summarizes the Company’s outstanding warrants as of December 31, 2022 and 2021: Summary of Outstanding Warrants Grant Date Grant Date Number of Exercise Fair Value Fair Value Warrants Price per Warrant Total Balance- January 1, 2021 Underwritten public offering 4,791,665 $ 6.00 $ 4.77 $ 22,856,242 Issuance of underwriter warrants 208,333 $ 7.50 $ 4.64 966,665 Balance- December 31, 2021 4,999,998 $ 23,822,907
Schedule of Fair Value of Warrants to Additional Paid in Capital	Schedule of Fair Value of Warrants to Additional Paid in Capital Percent Fair of Total Amount Value Fair Value Allocated Common Stock $ 25,000,000 51.2 % $ 12,800,000 Common Stock Purchase Warrants 23,822,907 48.8 % 12,200,000 Total $ 48,822,907 100 % $ 25,000,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Income tax expense differed from the expected expense computed by applying U.S. Federal income tax rate for the respective years ended as follows: Schedule of Effective Income Tax Rate Reconciliation December 31, 2022 December 31, 2021 Federal income tax benefit at statutory rate $ (3,712,008 ) $ (563,519 ) State income tax benefit (977,496 ) (148,393 ) Permanent differences 11,935 44,804 Change in valuation allowance 4,733,324 713,701 Other (55,755 ) (46,593 ) Total income tax expense $ - $ -
Schedule of Deferred Tax Assets and Liabilities	Schedule of Deferred Tax Assets and Liabilities December 31, 2022 December 31, 2021 Deferred income tax assets: Current: Research and development costs $ 343,087 $ - Other 59,018 4,050 Non-current: Net operating losses 3,381,215 1,201,974 Research and development costs 1,762,716 - Unvested stock options 204,380 11,835 Patents 92,417 90,480 Right-of-use assets 63,563 49,606 Gross deferred income tax assets 5,906,396 1,357,945 Less: valuation allowance (5,580,595 ) (847,269 ) Net deferred income tax asset 325,801 510,676 Deferred income tax liabilities: Current: Accrual to cash (11,228 ) (105,075 ) Non-current Property and equipment (314,573 ) (405,601 ) Gross deferred income tax liabilities (325,801 ) (510,676 ) Net deferred tax asset (liability) $ - $ -

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases
Summary of Components of Lease Cost	The components of lease cost for the years ended December 31, 2022 and 2021 were as follows: Summary of Components of Lease Cost 2022 2021 Operating lease cost $ 338,787 $ 338,787 Finance lease cost: Amortization of right-of-use assets 10,990 409,927 Interest on lease liabilities 2,804 26,504 Total finance lease cost 13,794 436,431 Total lease cost $ 352,581 $ 775,218
Summary of Lease Reported in Consolidated Balance Sheets	Amounts reported in the consolidated balance sheets as of December 31, 2022 and 2021 were as follows: Summary of Lease Reported in Consolidated Balance Sheets 2022 2021 Operating Leases: Operating lease right-of-use assets $ 630,618 $ 858,600 Other current liabilities 339,755 295,595 Operating lease liabilities 488,748 828,503 Total operating lease liabilities 828,503 1,124,098 Finance leases: Property and equipment 76,928 76,928 Accumulated amortization (44,988 ) (29,602 ) Property and equipment, net 31,940 47,326 Current installments of obligations under finance leases 16,053 15,096 Long-term portion of obligations under finance leases 21,487 37,534 Long-term portion of obligations under finance leases 21,487 37,534 Total finance lease liabilities $ 37,540 $ 52,630
Summary of Other Information Relating to Leases	Other information relating to leases as of December 31, 2022 and 2021 was as follows: Summary of Other Information Relating to Leases 2022 2021 Supplemental cash flow information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flow from operating leases $ 36,000 $ 433,172 Operating cash flow from finance leases 3,698 26,504 Financing cash flow from finance leases 15,090 436,259 Reductions to ROU assets resulting from reductions to lease obligations: Operating leases 227,981 196,245 Finance leases 10,990 409,927 Weighted average remaining lease term: Operating leases 25 39 Finance leases 27 39 Weighted average discount rate: Operating leases 11.62 % 11.57 % Finance leases 6.12 % 6.12 %
Summary of Maturity of Lease Liabilities	Maturities of lease liabilities under noncancellable leases as of December 31, 2022 are as follows: Summary of Maturity of Lease Liabilities Operating Finance leases leases 2023 414,800 17,900 2024 393,005 17,900 2025 132,580 4,475 Thereafter - - Total undiscounted lease payments 940,385 40,275 Less imputed interest (111,882 ) (2,742 ) Total lease liabilities $ 828,503 $ 37,533

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Net Loss Per Share Basic And Diluted	The following table sets forth the computation of the basic and diluted net loss per share for the year ended December 31, 2022 and 2021: Schedule of Net Loss Per Share Basic And Diluted 2022 2021 Numerator: Net loss $ (17,676,232 ) $ (20,709,991 ) Denominator: Weighted average common shares outstanding 11,309,412 7,413,579 Net loss per share, basic and diluted $ (1.56 ) $ (2.79 )
Schedule of Potentially Dilutive Securities	Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: Schedule of Potentially Dilutive Securities 2022 2021 Stock options issued under the 2021 Equity Incentive Plan 861,019 523,285 Common stock purchase warrants outstanding 4,999,998 4,999,998 Total 5,861,017 5,523,283

Nature of the Business and Li_2

Nature of the Business and Liquidity (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Aug. 10, 2022	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Proceeds from issuance of debt	$ 5,000,000
Proceeds from issuance of common stock				$ 20,374,218
Wainwright [Member] | Maximum [Member] | Subsequent Event [Member]
Property, Plant and Equipment [Line Items]
Proceeds from issuance of common stock		$ 2,650,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Feb. 28, 2021	Apr. 30, 2020	Dec. 31, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Federal deposit insurance corporation limit			$ 250,000
Impairment of long lived assets			$ 0	$ 0
Paycheck Protection Program [Member]
Short-Term Debt [Line Items]
Proceeds from loan	$ 236,457	$ 312,500

Schedule of Prepaid Expenses (D

Schedule of Prepaid Expenses (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Research and development	$ 1,377,391	$ 643,917
Insurance	472,152	761,594
Active pharmaceutical ingredients	209,156	264,361
Deferred capital raise costs	100,339
Professional fees	61,524
Dues and subscriptions	37,684
Other	20,698	28,481
Total prepaid expenses	$ 2,278,944	$ 1,698,353

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 4,964,853	$ 4,811,433
Less: accumulated depreciation	(2,060,066)	(1,666,055)
Property and equipment, net	2,904,787	3,145,378
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,565,997	2,509,126
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	2 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated useful life	7 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 145,754	145,754
Property and equipment, estimated useful life	7 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 41,898	41,898
Property and equipment, estimated useful life	5 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 471,505	471,505
Property and equipment, estimated useful life	5 years
Construction In Progress Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,739,699	$ 1,643,150

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 394,011	$ 708,317

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Interest	$ 292,339
Professional fees	314,446	71,570
Research and development		250,000
CIP- Equipment		279,730
Employee bonuses	175,625
Other	112,225
Total accrued expenses	$ 894,635	$ 601,300

Related Party Notes Payable (De

Related Party Notes Payable (Details Narrative) - USD ($)		12 Months Ended
	Aug. 10, 2022	Dec. 31, 2022
Issuance of debt	$ 5,000,000
Interest expense		$ 292,339
Werth Family Investment Associates LLC [Member]
Issuance of debt	$ 5,000,000	$ 5,000,000
Unsecured interest percentage	15%
Debt instrument, description	Outstanding principal and all accrued and unpaid interest are due and payable on August 8, 2025, or 120 days following written demand made by WFIA during the first five business days of a calendar quarter beginning April 1, 2023.

Members_ Capital (Details Narra

Members’ Capital (Details Narrative) - USD ($) $ in Millions	Dec. 31, 2022	Dec. 31, 2021
Preferred Units Class F [Member]
Preferred Units [Line Items]
Preferred units, issued		3,243,201
Preferred Units Class F [Member] | CTx Board [Member]
Preferred Units [Line Items]
Preferred units, authorized	6,984,985
Issuance of preferred uniits	$ 11.3
Preferred Units Class G [Member]
Preferred Units [Line Items]
Preferred units, issued		3,243,201
Preferred Units Class G [Member] | CTx Board [Member]
Preferred Units [Line Items]
Preferred units, issued	2,998,184
Preferred units, authorized	12,000,000
Issuance of preferred uniits	$ 6.7

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - Equity Incentive Plan (PIU) [Member] $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($) shares
Defined Benefit Plan Disclosure [Line Items]
Number of stock options, outstanding at Beginning balance	8,142,461
Number of stock options, issued	357,539
Distribution of Thresholds, issued | $	$ 160
Number of stock options, Forfeited
Converted to common shares upon Reorganization Merger, shares	(8,500,000)
Number of stock options, outstanding at Ending balance
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Distribution of Thresholds, outstanding | $	$ 25
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Distribution of Thresholds, outstanding | $	$ 120

Schedule of Various Distributio

Schedule of Various Distribution Thresholds (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Distribution Threshold $25 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017	$ 4,753,000
2018
2019
2020
Total	4,753,000
Distribution Threshold $40 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017	125,200
2018	661,525
2019
2020
Total	786,725
Distribution Threshold $75 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018	217,725
2019
2020
Total	217,725
Distribution Threshold $80 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018	22,883
2019
2020	1,476,126
Total	1,499,009
Distribution Threshold $90 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018
2019	377,524
2020
Total	377,524
Distribution Threshold $120 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018
2019	458,924
2020	49,554
Total	508,478
Distribution Threshold $160 Million [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017
2018
2019
2020
2021	357,539
Total	357,539
Distribution Threshold [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
2017	4,878,200
2018	902,133
2019	836,448
2020	1,525,680
2021	357,539
Total	$ 8,500,000

Profits Interest Plan (Details

Profits Interest Plan (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Noncash compensation expense		$ 12,738,088
Equity Incentive Plan (PIU) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock option, granted	8,500,000
Conversion of stock into common shares	1,158,008
Noncash compensation expense	$ 12,700,000
Equity Incentive Plan (PIU) [Member] | General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Noncash compensation expense	8,200,000
Equity Incentive Plan (PIU) [Member] | Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Noncash compensation expense	$ 4,500,000

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($)		12 Months Ended
	Sep. 30, 2021	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Common stock, shares authorized		240,000,000	240,000,000
Common stock, par value		$ 0.0001	$ 0.0001
Preferred stock, shares authorized		10,000,000	10,000,000
Preferred stock, par value		$ 0.0001	$ 0.0001
Number of shares of common stock issued		11,309,412	11,309,412
Common stock, shares outstanding		11,309,412	11,309,412
Dividend common stock shares	0.029
Aggregate common stock dividend	448,045
Reverse stock splits, description		On October 12, 2021, Cingulate effected a reverse stock split of its issued and outstanding shares of common stock at a ratio of 0.699-for-1, and on November 29, 2021, Cingulate effected a second reverse stock split of its issued and outstanding shares of common stock at a ratio of 0.64259-for-1 (the “Reverse Stock Splits”). No fractional shares of common stock were issued in connection with either of the Reverse Stock Splits, and all such fractional interests were rounded down to the nearest whole number. All share data, per share data and related information for all periods presented in the accompanying consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Splits.
Dividend Declared [Member]
Subsidiary, Sale of Stock [Line Items]
Dividends declared		$ 0
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of common stock issued			4,166,666
Share issued price per share			$ 6
Proceeds from public offering			$ 20,400,000
Reorganization Merger [Member]
Subsidiary, Sale of Stock [Line Items]
Number of shares of common stock issued		7,142,746
Common stock, shares outstanding		7,142,746

Summary of Option Activity (Det

Summary of Option Activity (Details) - 2021 Equity Incentive Plan [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of stock options, outstanding at Beginning balance	523,285
Number of Shares, Granted	417,632	523,285
Weighted Average Exercise Price, Granted	$ 1.72	$ 6
Weighted Average Remaining Contractual Life (Years) Outstanding, Grants	9 years 2 months 1 day	9 years 11 months 8 days
Aggregate intrinsic value, Grants
Number of Shares, Exercised
Number of Shares, Forfeitures or expirations	(79,898)
Weighted Average Exercise Price, Forfeitures or expirations	$ 3.46
Number of stock options, outstanding at Ending balance	861,019	523,285
Weighted Average Exercise Price, Outstanding Ending Balance	$ 4.16
Weighted Average Remaining Contractual Life (Years) Outstanding	9 years 18 days
Aggregate intrinsic value, Outstanding Ending
Shares, Vested and expected to vest	861,019
Shares, Exercisable	169,027

Schedule of Fair Value Assumpti

Schedule of Fair Value Assumption (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Risk-free interest rate	1.889%	0.012%
Expected term (in years)	5 years 11 months 23 days	6 years 3 months
Expected volatility	1.126%	1.134%
Expected dividend yield	0%	0%

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 800,796	$ 43,835
Expected dividend yield	0%	0%
Grant-date fair value of options		$ 5.13
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant-date fair value of options	$ 0.86
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Grant-date fair value of options	$ 1.16
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock-based compensation expense	$ 800,796	$ 43,835
2021 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, description	The number of shares of common stock available for issuance under the 2021 Plan will automatically increase on January 1st of each year until the expiration of the 2021 Plan, in an amount equal to 5% percent of the total number of shares of our common stock outstanding on December 31st of the preceding calendar year, on a fully diluted basis, unless the board of directors takes action prior thereto to provide that there will not be an increase in the share reserve for such year or that the increase in the share reserve for such year will be of a lesser number of shares of common stock than would otherwise occur.
Unrecognized compensation cost	$ 2,089,509	$ 2,637,895
Expected to be recognized, term	4 years
2021 Equity Incentive Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock options	1,066,791
2021 Equity Incentive Plan [Member] | Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares common stock options	1,927,810

Summary of Outstanding Warrants

Summary of Outstanding Warrants (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) $ / shares shares
Common Stock Purchase Warrants
Number of warrants underwritten public offering | shares	4,791,665
Exercise price of warrants underwritten public offering	$ 6
Grant date fair value per warrant underwritten public offering	$ 4.77
Grant date fair value underwritten public offering | $	$ 22,856,242
Number of warrants issuance of underwriter warrants | shares	208,333
Exercise price of warrants issuance of underwriter warrants	$ 7.50
Exercise price of warrants issuance of underwriter warrants	$ 4.64
Grant date fair value issuance of underwriter warrants | $	$ 966,665
Number of warrants, ending balance | shares	4,999,998
Grant date fair value, ending balance | $	$ 23,822,907

Schedule of Fair Value of Warra

Schedule of Fair Value of Warrants to Additional Paid in Capital (Details)	12 Months Ended
	Dec. 31, 2022 USD ($)
Fair value, Total	$ 48,822,907
Percent of Total Fair Value, Total	100%
Amount Allocated, Total	$ 25,000,000
Common Stock [Member]
Fair value, Total	$ 25,000,000
Percent of Total Fair Value, Total	51.20%
Amount Allocated, Total	$ 12,800,000
Common Stock Purchase Warrants [Member]
Fair value, Total	$ 23,822,907
Percent of Total Fair Value, Total	48.80%
Amount Allocated, Total	$ 12,200,000

Common Stock Purchase Warrant_2

Common Stock Purchase Warrants (Details Narrative)	12 Months Ended
	Dec. 31, 2022 $ / shares shares	Dec. 31, 2021
Warrants exercisable, description	warrants are exercisable from December 10, 2021 through December 10, 2026.
Expected life	5 years 11 months 23 days	6 years 3 months
IPO [Member]
Purchase of warrants shares | shares	208,333
Purchase of warrants price per share | $ / shares	$ 7.50
Warrants exercisable, description	warrants are exercisable from June 7, 2022 through December 10, 2026.
Warrant [Member]
Purchase of warrants shares | shares	4,791,665
Purchase of warrants price per share | $ / shares	$ 6
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants measurement input	0.0082
Warrant [Member] | Measurement Input, Expected Term [Member]
Expected life	5 years
Warrant [Member] | Measurement Input, Price Volatility [Member]
Warrants measurement input	1.24
Warrant [Member] | IPO [Member]
Purchase of warrants shares | shares	4,166,666
Purchase of warrants price per share | $ / shares	$ 6
Warrant [Member] | Over-Allotment Option [Member]
Purchase of warrants shares | shares	624,999
Purchase of warrants price per share | $ / shares	$ 0.001

Schedule of Effective Income Ta

Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal income tax benefit at statutory rate	$ (3,712,008)	$ (563,519)
State income tax benefit	(977,496)	(148,393)
Permanent differences	11,935	44,804
Change in valuation allowance	4,733,324	713,701
Other	(55,755)	(46,593)
Total income tax expense

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Research and development costs	$ 343,087
Other	59,018	4,050
Net operating losses	3,381,215	1,201,974
Research and development costs	1,762,716
Unvested stock options	204,380	11,835
Patents	92,417	90,480
Right-of-use assets	63,563	49,606
Gross deferred income tax assets	5,906,396	1,357,945
Less: valuation allowance	(5,580,595)	(847,269)
Net deferred income tax asset	325,801	510,676
Accrual to cash	(11,228)	(105,075)
Property and equipment	(314,573)	(405,601)
Gross deferred income tax liabilities	(325,801)	(510,676)
Net deferred tax asset (liability)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Deferred income tax expense benefit	$ 0	$ 0
Valuation allowance	$ 5,580,595	$ 847,269

Summary of Components of Lease

Summary of Components of Lease Cost (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating lease cost	$ 338,787	$ 338,787
Amortization of right-of-use assets	10,990	409,927
Interest on lease liabilities	2,804	26,504
Total finance lease cost	13,794	436,431
Total lease cost	$ 352,581	$ 775,218

Summary of Lease Reported in Co

Summary of Lease Reported in Consolidated Balance Sheets (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating lease right-of-use assets	$ 630,618	$ 858,600
Other current liabilities	339,755	295,595
Operating lease liabilities	488,748	828,503
Total operating lease liabilities	828,503	1,124,098
Property and equipment	76,928	76,928
Accumulated amortization	(44,988)	(29,602)
Property and equipment, net	31,940	47,326
Current installments of obligations under finance leases	16,053	15,096
Long-term portion of obligations under finance leases	21,487	37,534
Total finance lease liabilities	$ 37,540	$ 52,630

Summary of Other Information Re

Summary of Other Information Relating to Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Leases
Operating cash flow from operating leases	$ 36,000	$ 433,172
Operating cash flow from finance leases	3,698	26,504
Financing cash flow from finance leases	15,090	436,259
Reductions to ROU assets resulting from reductions to lease obligations: Operating leases	227,981	196,245
Reductions to ROU assets resulting from reductions to lease obligations: Finance leases	$ 10,990	$ 409,927
Weighted average remaining lease term: Operating leases	25 months	39 months
Weighted average remaining lease term: Finance leases	27 months	39 months
Weighted average discount rate: operating leases	11.62%	11.57%
Weighted average discount rate: Finance leases	6.12%	6.12%

Summary of Maturity of Lease Li

Summary of Maturity of Lease Liabilities (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Total lease liabilities	$ 828,503	$ 1,124,098
Total lease liabilities	37,540	$ 52,630
Operating Lease [Member]
Lessee, Lease, Description [Line Items]
2023	414,800
2024	393,005
2025	132,580
Thereafter
Total undiscounted lease payments	940,385
Less imputed interest	(111,882)
Total lease liabilities	828,503
Finance Leases [Member]
Lessee, Lease, Description [Line Items]
2023	17,900
2024	17,900
2025	4,475
Thereafter
Total undiscounted lease payments	40,275
Less imputed interest	(2,742)
Total lease liabilities	$ 37,533

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	1 Months Ended			12 Months Ended
	Apr. 30, 2020	Dec. 31, 2019	Jun. 30, 2019	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018	Jan. 31, 2021
Lessee, Lease, Description [Line Items]
Rent expense per month	$ 1,491	$ 37,072				$ 61,786
Operating lease extended term		this lease was extended for a period of twenty-four months with a monthly lease payment of $37,072.
Lease description				In April 2020, the Company entered into a 60-month lease agreement for office furniture under a lease classified as a financing lease as title of the furniture transfers to the Company at the end of the lease term. Monthly lease payments are $1,491. The leased furniture is amortized on a straight-line basis over 7 years. The imputed interest rate relating to the lease obligation is 6.12% and the maturity date is March 2025.
Percentage of imputed interest rat, lease obligation					6.12%
Kansas City Office [Member]
Lessee, Lease, Description [Line Items]
Lease term			5 years
Lease incentive by lessor of tenant improvements			$ 201,600
Kansas City Office [Member] | Minimum [Member]
Lessee, Lease, Description [Line Items]
Rent expense per month			30,453
Kansas City Office [Member] | Maximum [Member]
Lessee, Lease, Description [Line Items]
Rent expense per month			$ 33,145
Office Facilities Space [Member]
Lessee, Lease, Description [Line Items]
Lease term							3 years
Rent expense per month				$ 3,000	$ 3,000

Schedule of Net Loss Per Share

Schedule of Net Loss Per Share Basic And Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Net loss	$ (17,676,232)	$ (20,709,991)
Weighted average common shares outstanding	11,309,412	7,413,579
Net loss per share, basic and diluted	$ (1.56)	$ (2.79)

Schedule of Potentially Dilutiv

Schedule of Potentially Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	5,861,017	5,523,283
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	861,019	523,285
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	4,999,998	4,999,998

License Agreement (Details Narr

License Agreement (Details Narrative) - Licensing Agreements [Member] - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Phase 3 Clinical Trial [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	$ 250,000
New Drug Application [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	250,000
CTx-1301 and CTx-1302 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	250,000
CTx-2103 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	500,000
CTx-2103 [Memer]
Indefinite-Lived Intangible Assets [Line Items]
Milestone payment	$ 250,000
CTx-1301 [Member]
Indefinite-Lived Intangible Assets [Line Items]
Accrued milestone payment		$ 250,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)		12 Months Ended
	Aug. 10, 2022	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Due to related party on lease		$ 0	$ 0
Issuance of debt	$ 5,000,000
Interest expense		292,339
Accrued interest		292,339
Werth Family Investment Associates LLC [Member]
Related Party Transaction [Line Items]
Issuance of debt	$ 5,000,000	5,000,000
Office Facilities Space [Member]
Related Party Transaction [Line Items]
Annual rental expense		$ 36,000	36,000
IPO [Member] | Laidlaw and Company UKLtd [Member]
Related Party Transaction [Line Items]
Payments of discounts and commissions			$ 500,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Jan. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Proceeds from issuance of common stock			$ 20,374,218
Wainwright [Member] | Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Sale of stock commission percent	3%
Wainwright [Member] | Maximum [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from issuance of common stock	$ 2,650,000